Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? Abbott trades at a 18x forward P/E with $7.4B in free cash flow, while Intuitive Surgical commands a 39x multiple backed by zero debt and 20% revenue growth.
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.
These 3 Dividend Stocks Yield Less Than 10-Year Treasuries Over 5%. Here's Why They Are Better Buys Anyway. Treasuries pay more today, but these three healthcare dividend payers offer something Treasuries can't: growth in both the payout and the stock.
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? Intuitive Surgical is beating estimates and raising margins while its installed base keeps expanding. Abbott is executing steadily across a diversified portfolio but growing at a more measured pace.
3 High-Yielding Dividend Stocks That Are No-Brainer Buys for Retirees and Risk-Averse Investors These quality, low-volatility stocks yield between 2.4% and 3.1%, and have been raising their payouts for decades.
Abbott Laboratories vs. Intuitive Surgical: Recent Quarterly Revenue Trends Reveal a Classic Investing Truth Abbott leads in absolute revenue, but Intuitive Surgical's growth rate tells a different story over the past eight quarters.
3 Dividend Stocks to Buy and Hold for 10 Years They have a knack for increasing their dividends even when facing challenges.
Why Wall Street Is Becoming Even More Bullish About This Dividend King Analysts keep raising their price targets on this 54-year dividend raiser. Here are the reasons behind the newfound confidence.
SCHD's Stunning Reversal: Schwab's Flagship Dividend ETF Is Up 29% and Climbing Given what's going on in the world and in the market, perhaps it's natural that SCHD is surging.
If a Stock Market Crash Is Coming, Investors Will Want to Own This Dividend King Worried about a pullback? This Dividend King pairs a 54-year streak with catalysts that could provide income even if the market crashes.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.
3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King) Owning these dividend stocks could be a simple way to make money over the long term.
Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead. AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.
